294 related articles for article (PubMed ID: 24471304)
1. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
2. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
Xie YM; Wang X; Wang N; Chang YP
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
[TBL] [Abstract][Full Text] [Related]
5. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
Zhang W; Xie YM; Yu WY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
[TBL] [Abstract][Full Text] [Related]
6. Expert consensus for postmarketing Chinese medicine intensive hospital safety monitoring.
Liao X; Zhang W; Xie YM; Tian F; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W
Chin J Integr Med; 2014 Jul; ():. PubMed ID: 24993333
[TBL] [Abstract][Full Text] [Related]
7. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
9. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
10. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
[TBL] [Abstract][Full Text] [Related]
11. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
[TBL] [Abstract][Full Text] [Related]
12. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
13. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)].
Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
[TBL] [Abstract][Full Text] [Related]
15. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
Yan BH; Peng C; Xie YM; Wang YY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.
Li J; Li M; Li L; Ma L; Cao A; Wen A; Chen W; Li L; Liang Y; Deng J
BMC Pharmacol Toxicol; 2022 Jul; 23(1):51. PubMed ID: 35842685
[TBL] [Abstract][Full Text] [Related]
17. [Thought on several problems of clinical revaluation of post-marketing herb research].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
19. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
